Qpex Biopharma

Qpex Biopharma is a San Diego-based biotech founded in 2018, dedicated to combating antimicrobial resistance through innovative anti-infective therapies. The company employs a science platform focused on improving existing drug classes, targeting underexploited mechanisms, and developing non-antibiotic resistance breakers. As a private, Shionogi-backed entity, it is advancing a pipeline of novel agents designed to treat serious, multidrug-resistant infections, positioning itself in a critical but challenging market with high unmet medical need.

Multi-pronged platform focused on improving existing antibiotic classes, targeting underexploited bacterial mechanisms, and discovering non-antibiotic adjuvants (e.g., beta-lactamase inhibitors) to neutralize resistance. Aims to address both class-based and intrinsic resistance (permeability, efflux).

Operates in a sparse but high-stakes competitive landscape for novel antibiotics. Competitors include large pharma with legacy interests (e.g., Pfizer, Merck) and specialized biotechs (e.g., Entasis (now Innoviva), Venatorx, Nabriva). Differentiation is achieved through targeted pathogen focus, novel resistance-breaking mechanisms, and the unique Shionogi partnership for global scale.